CN1943708A - A Chinese traditional medicinal composition and its preparation method - Google Patents
A Chinese traditional medicinal composition and its preparation method Download PDFInfo
- Publication number
- CN1943708A CN1943708A CN 200510105937 CN200510105937A CN1943708A CN 1943708 A CN1943708 A CN 1943708A CN 200510105937 CN200510105937 CN 200510105937 CN 200510105937 A CN200510105937 A CN 200510105937A CN 1943708 A CN1943708 A CN 1943708A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- volatile oil
- weight portions
- breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
This invention provides a Chinese traditional medicinal composition belonging to the field of the Chinese traditional medince. The composition is prepare by using green tangerine peel(stir-fried), common selfheal spike, bulbus fritilariae, kelp and frankinense (dipped in venger)in accordance with specific processing technology.It has better curative effects in treating stagnation of qi, phlegm stagnation and blood stasis of patients suffered from cystic hyperplasia of breast. Their symptoms are mamamary distending pain which is even heavier before menstruation comes,mammary occur tumour and feel pain when touching,distending in sternocostal part,dysphoria and easy to be angery, tomgue coat is thin and in white color, the pulse condition is thin and slipy. The invention also reveals preparing method.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, belong to the field of Chinese medicines; The preparation method that also relates to this Chinese medicine composition simultaneously.
Background technology
Cyclomastopathy is commonly encountered disease, frequently-occurring disease, and sickness rate reaches 30～50%.Cyclomastopathy such as untimely treatment have certain canceration rate, endanger the healthy of numerous women.Clinically mastalgia and the lump in breasies of showing as of cyclomastopathy more.Western medical treatment mainly adopts hormone therapy at present, but the hormone therapy cycle is long, the relapse rate height, and side effect is big, and easily causes the equilibrated disorder of hormone in vivo.Adopt the Chinese traditional treatment hyperplasia of mammary glands, side effect is less, the objective of the invention is for a kind of treatment cystic hyperplasia of breast of determined curative effect is provided, and the Chinese patent medicine of mastalgia, thus reach treating both the principal and secondary aspects of a disease, improve curative effect, reduce the purpose of recurrence.
Summary of the invention
The present invention seeks to be achieved through the following technical solutions:
Medicine of the present invention is made by following bulk drugs:
Pericarpium Citri Reticulatae Viride (stir-fry) 450～550 weight portion Spica Prunellaes 550～650 weight portions
Bulbus Fritillariae Thunbergii 450～550 weight portion Thallus Laminariae (Thallus Eckloniae)s 550～650 weight portions
Olibanum (vinegar system) 400～500 weight portions
Medicine optimum weight part proportioning of the present invention is:
Pericarpium Citri Reticulatae Viride (stir-fry) 500 weight portion Spica Prunellaes 600 weight portions
Bulbus Fritillariae Thunbergii 500 weight portion Thallus Laminariae (Thallus Eckloniae)s 600 weight portions
Olibanum (vinegar system) 450 weight portions
Above crude drug can be made multiple oral formulations, comprises tablet, capsule, granule, soft capsule, pill etc., and the common preparation process of these preparations is:
The above five tastes are got Pericarpium Citri Reticulatae Viride, Olibanum extraction volatile oil, and the aqueous solution after distillation device is in addition collected; Three flavors such as medicinal residues and all the other Spica Prunellaes decoct with water collecting decoction and above-mentioned aqueous solution 2～3 times, filter, concentrate, be cooled to below 40 ℃, add equivalent ethanol, left standstill 24 hours, filter, precipitation is washed with Diluted Alcohol, merging filtrate and washing liquid reclaim ethanol and concentrate drying, pulverize, powder gets dry extract.Other gets volatile oil, uses the beta-schardinger dextrin-inclusion, the leaching inclusion complex, and 50 ℃ of dryings, standby.Get above-mentioned dried cream powder and volatile oil beta-CD inclusion complex mixing, add right amount of auxiliary materials, make required dosage form.
Common dosage form and preparation method are:
In the extractum compositions, add disintegrating agent, binding agent, granulate, add lubricant, be pressed into tablet.
In the extractum compositions, add disintegrating agent, binding agent, be prepared into pill.
In the extractum compositions, add substrate, suspending agent, wetting agent, be prepared into soft capsule.
In the extractum compositions, add fluidizer and incapsulate, be prepared into capsule.
Best preparation method is:
The above five tastes are got Pericarpium Citri Reticulatae Viride, Olibanum extraction volatile oil, and the aqueous solution after distillation device is in addition collected; Three flavors such as medicinal residues and all the other Spica Prunellaes decoct with water secondary, each 1.5 hours, collecting decoction and above-mentioned aqueous solution filter, and it is 1.05～1.10 (65 ℃) that filtrate is concentrated into relative density, be cooled to below 40 ℃, add equivalent ethanol, left standstill 24 hours, filter, precipitation is washed with Diluted Alcohol 2500ml, merging filtrate and washing liquid, reclaim ethanol and be concentrated into the thick paste that relative density is 1.30～1.35 (65 ℃), dry below 80 ℃, pulverize, powder gets dry extract.Other gets volatile oil, uses the beta-schardinger dextrin-inclusion, the leaching inclusion complex, and 50 ℃ of dryings, standby.Get above-mentioned dried cream powder and volatile oil beta-CD inclusion complex mixing, add right amount of auxiliary materials, make granule.
The stagnation of QI due to depression of the liver that this product can be used for treating the cystic hyperplasia of breast patient expectorant blood coagulation blood stasis syndrome of holding concurrently is waited, disease is seen: distending pain of the breast, through before increasing the weight of lump in breast, the pain of touching, breast side of body feeling of distension and oppression, fidgety irritability, thin white fur of tongue, pulse condition string or stringy and thready pulse, stringy and rolling pulse are for determining drug effect, this product has been carried out pharmacodynamics test research, and particles used dose is by the preparation of best proportioning of the present invention and optimum process and get in the test.Concrete test is as follows:
Test method: 120 of the SD female rats of selection normal health, body weight 180～200g are divided into 6 groups, 20 every group at random.Except that the normal control group, each the group all by body weight 0.15mgPkg subcutaneous injection estradiol benzoate, the next day once, totally 15 times; In moulding 3 metering groups of this product granule (5,10,20gPkg) and android group (50mgPkg) gastric infusion every day once simultaneously, model group and normal control group are given the equivalent distilled water, continuous 32d.24h after the last administration implements behind the etherization from heart extracting blood, with measured by radioimmunoassay estradiol, lactotropin, 3 (being called for short T3), thyroxine (abbreviation T4) (the results are shown in Table 3) rat.Take to take off the cervical vertebra method afterwards and put to death all rats, the reuse precimeter measures each Mus axil fore udder diameter, get the uterus ovary weighs, gets mammary gland tissue and do the pathology inspection, keep the score by cyclomastopathy pathological changes standard (seeing Table 1), and represent cyclomastopathy degree (the results are shown in Table 2) with every summation of keeping the score.
The table 1 cyclomastopathy pathological changes standard of keeping the score
| Breast lesion | Score value | |||
| 0 | 1 | 2 | 3 | |
| Lobules of mammary gland number breast chamber expansion epithelial hyperplasia secretions interstitial fibers hypertrophy lymphocytic infiltration | Not obvious not obvious no not obvious nothing | 1～2 light column obviously has less | Multiple layer is more in 3～4 | More than 〉=5 heavy 〉=3 layer |
The influence of table 2 pair rat mammary gland model of hyperplasia
| Group | The cyclomastopathy score value | Papilla diameter (mm) | Uterus coefficient (gP100g) | Ovary coefficient (gP100g) |
| Dose particles high dose in the normal control group model matched group android group granule low dosage granule | 0±0** 11.03±2.11 7.51±2.15** 10.28±2.47 9.96±1.44 6.37±1.63** | 0.81±0.22** 2.12±0143 1.23±0.38** 1.76±0.56 1.31±0.57** 1.34±0.52** | 0.132±0.023** 0.358±0.083 0.285±0.058** 0.337±0.124** 0.324±0.116** 0.268±0.044** | 0.004±0.001** 0.051±0.016 0.036±0.009** 0.047±0.019 0.033±0.008** 0.035±0.015** |
Annotate: t value method, compare * P＜0.05 * * P＜0.01 with model group
The influence of table 3 pair cyclomastopathy rat estradiol, lactotropin, T3, T4
| Group | Estradiol (pgPml) | Lactotropin (uIUPml) | T3(ngPml) | T4(ngPml) |
| Dose particles high dose in the normal control group model matched group android group granule low dosage granule | 7.6±3.2 465.3±428.0 242.4±136.6* 191.7±121.0** 53.1±49.8** 42.5±27.3** | 1.6±2.13** 10.40±0.01 7.9±27.9** 9.36±13.87** 8.57±10.57** 3.02±4.17** | 5.2±1.7 5.6±1.5 3.3±0.5** 4.1±1.6** 3.2±0.3** 1.1±0.3** | 53.1±22.7 37.6±10.1 28.9±9.5** 34.3±10.5 43.7±14.1 35.9±10.7 |
Annotate: t value method, compare * P＜0.05 * * P＜0.01 with model group
Result of the test shows that three dosage groups of Chinese medicine composition of the present invention all have the obvious suppression effect to the secretion of various female bodies of gland, and the hamartoplasia that estrogen is caused also has tangible contraction.
Below by implementing to further specify technical scheme of the present invention, but this applies for that claimed scope is not limited in the described content of embodiment.
The specific embodiment:
Embodiment 1
[prescription] Pericarpium Citri Reticulatae Viride (stir-fry) 500g Spica Prunellae 600g
Bulbus Fritillariae Thunbergii 500g Thallus Laminariae (Thallus Eckloniae) 600g
Olibanum (vinegar system) 450g
[method for making] above five tastes are got Pericarpium Citri Reticulatae Viride, Olibanum extraction volatile oil, and the aqueous solution after distillation device is in addition collected; Three flavors such as medicinal residues and all the other Spica Prunellaes decoct with water secondary, each 1.5 hours, collecting decoction and above-mentioned aqueous solution filter, and it is 1.05～1.10 (65 ℃) that filtrate is concentrated into relative density, be cooled to below 40 ℃, add equivalent ethanol, left standstill 24 hours, filter, precipitation is washed with Diluted Alcohol 2500ml, merging filtrate and washing liquid, reclaim ethanol and be concentrated into the thick paste that relative density is 1.30～1.35 (65 ℃), dry below 80 ℃, pulverize, powder gets dry extract.Other gets volatile oil, uses the beta-schardinger dextrin-inclusion, the leaching inclusion complex, and 50 ℃ of dryings, standby.Get above-mentioned dried cream powder and volatile oil beta-CD inclusion complex mixing, the adding lactose is an amount of, with 70% alcohol granulation, and 50 ℃ of dryings, granulate is made 1000g, promptly.
Embodiment 2
[prescription] Pericarpium Citri Reticulatae Viride (stir-fry) 500g Spica Prunellae 600g
Bulbus Fritillariae Thunbergii 500g Thallus Laminariae (Thallus Eckloniae) 600g
Olibanum (vinegar system) 450g
[method for making] above five tastes are got Pericarpium Citri Reticulatae Viride, Olibanum extraction volatile oil, and the aqueous solution after distillation device is in addition collected; Three flavors such as medicinal residues and all the other Spica Prunellaes decoct with water secondary, each 1.5 hours, collecting decoction and above-mentioned aqueous solution filter, and it is 1.05～1.10 (65 ℃) that filtrate is concentrated into relative density, be cooled to below 40 ℃, add equivalent ethanol, left standstill 24 hours, filter, precipitation is washed with Diluted Alcohol 2500ml, merging filtrate and washing liquid, reclaim ethanol and be concentrated into the thick paste that relative density is 1.30～1.35 (65 ℃), dry below 80 ℃, pulverize, powder gets dry extract.Other gets volatile oil, uses the beta-schardinger dextrin-inclusion, the leaching inclusion complex, and 50 ℃ of dryings, standby.Get above-mentioned dried cream powder and volatile oil beta-CD inclusion complex mixing, add carboxymethylstach sodium 40g, microcrystalline Cellulose 60g is with 70% ethanol moistening, cross 16 mesh sieve system granules, dry (50～60 ℃), granulate adds magnesium stearate 1g, it is an amount of to add carboxymethylstach sodium again, and tabletting is made 1000, promptly.
Embodiment 3:
[prescription] Pericarpium Citri Reticulatae Viride (stir-fry) 500g Spica Prunellae 600g
Bulbus Fritillariae Thunbergii 500g Thallus Laminariae (Thallus Eckloniae) 600g
Olibanum (vinegar system) 450g
[method for making] above five tastes are got Pericarpium Citri Reticulatae Viride, Olibanum extraction volatile oil, and the aqueous solution after distillation device is in addition collected; Three flavors such as medicinal residues and all the other Spica Prunellaes decoct with water secondary, each 1.5 hours, collecting decoction and above-mentioned aqueous solution filter, and it is 1.05～1.10 (65 ℃) that filtrate is concentrated into relative density, be cooled to below 40 ℃, add equivalent ethanol, left standstill 24 hours, filter, precipitation is washed with Diluted Alcohol 2500ml, merging filtrate and washing liquid, reclaim ethanol and be concentrated into the thick paste that relative density is 1.30～1.35 (65 ℃), dry below 80 ℃, pulverize, powder gets dry extract.Other gets volatile oil, uses the beta-schardinger dextrin-inclusion, the leaching inclusion complex, and 50 ℃ of dryings, standby.Get above-mentioned dried cream powder and volatile oil beta-CD inclusion complex mixing, make soft material, granulate, encapsulated, promptly.
Claims (6)
1, a kind of Chinese medicine composition is characterized in that this Chinese medicine composition made by following raw material medicaments:
Pericarpium Citri Reticulatae Viride 450～550 weight portion Spica Prunellaes 550～650 weight portions
Bulbus Fritillariae Thunbergii 450～550 weight portion Thallus Laminariae (Thallus Eckloniae)s 550～650 weight portions
Olibanum 400～500 weight portions
2, Chinese medicine composition according to claim 1 is characterized in that this Chinese medicine composition made by following raw material medicaments:
Pericarpium Citri Reticulatae Viride 500 weight portion Spica Prunellaes 600 weight portions
Bulbus Fritillariae Thunbergii 500 weight portion Thallus Laminariae (Thallus Eckloniae)s 600 weight portions
Olibanum 450 weight portions
3, Chinese medicine composition as claimed in claim 1 or 2 is characterized in that making multiple oral formulations, comprises tablet, capsule, granule, soft capsule, pill etc.
4, the preparation method of Chinese medicine composition as claimed in claim 1 or 2 is characterized in that this method is:
The above five tastes are got Pericarpium Citri Reticulatae Viride, Olibanum extraction volatile oil, and the aqueous solution after distillation device is in addition collected; Three flavors such as medicinal residues and all the other Spica Prunellaes decoct with water collecting decoction and above-mentioned aqueous solution 2～3 times, filter, concentrate, be cooled to below 40 ℃, add equivalent ethanol, left standstill 24 hours, filter, precipitation is washed with Diluted Alcohol, merging filtrate and washing liquid reclaim ethanol and concentrate drying, pulverize, powder gets dry extract.Other gets volatile oil, uses the beta-schardinger dextrin-inclusion, the leaching inclusion complex, and 50 ℃ of dryings, standby.Get above-mentioned dried cream powder and volatile oil beta-CD inclusion complex mixing, add right amount of auxiliary materials, make required dosage form.
5, the preparation method of Chinese medicine composition as claimed in claim 1 or 2 is characterized in that this method is:
The above five tastes are got Pericarpium Citri Reticulatae Viride, Olibanum extraction volatile oil, and the aqueous solution after distillation device is in addition collected; Three flavors such as medicinal residues and all the other Spica Prunellaes decoct with water secondary, each 1.5 hours, collecting decoction and above-mentioned aqueous solution filter, and it is 1.05～1.10 that filtrate is concentrated into 65 ℃ of relative densities, be cooled to below 40 ℃, add equivalent ethanol, left standstill 24 hours, filter, precipitation is washed with Diluted Alcohol 2500ml, merging filtrate and washing liquid, reclaiming ethanol and being concentrated into 65 ℃ of relative densities is 1.30～1.35 thick paste, dry below 80 ℃, pulverize, powder gets dry extract.Other gets volatile oil, uses the beta-schardinger dextrin-inclusion, the leaching inclusion complex, and 50 ℃ of dryings, standby.Get above-mentioned dried cream powder and volatile oil beta-CD inclusion complex mixing, add right amount of auxiliary materials, make required dosage form.
6, the Chinese medicine composition stagnation of QI due to depression of the liver that is used for the treatment of the cystic hyperplasia of breast patient in the preparation expectorant blood coagulation blood stasis syndrome of holding concurrently is waited as claimed in claim 1 or 2, disease is seen: distending pain of the breast, through before increasing the weight of, lump in breast, the pain of touching, breast side of body feeling of distension and oppression, fidgety irritability, the application in the medicine of thin white fur of tongue, pulse condition string or stringy and thready pulse, stringy and rolling pulse.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510105937 CN1943708A (en) | 2005-10-08 | 2005-10-08 | A Chinese traditional medicinal composition and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510105937 CN1943708A (en) | 2005-10-08 | 2005-10-08 | A Chinese traditional medicinal composition and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1943708A true CN1943708A (en) | 2007-04-11 |
Family
ID=38043502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510105937 Pending CN1943708A (en) | 2005-10-08 | 2005-10-08 | A Chinese traditional medicinal composition and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1943708A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579846A (en) * | 2012-03-09 | 2012-07-18 | 广西强寿药业集团有限公司 | Chinese patent medicament wind-calming and pain-relieving granules for treating migraine and preparation method thereof |
| CN102716420A (en) * | 2012-06-19 | 2012-10-10 | 吴金虎 | Medicament for treating cyclomastopathy and hyperprolactinemia and preparation method of medicament |
| CN106075027A (en) * | 2016-07-19 | 2016-11-09 | 辽宁中医药大学 | A kind of Chinese medicine composition treating cyclomastopathy |
-
2005
- 2005-10-08 CN CN 200510105937 patent/CN1943708A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579846A (en) * | 2012-03-09 | 2012-07-18 | 广西强寿药业集团有限公司 | Chinese patent medicament wind-calming and pain-relieving granules for treating migraine and preparation method thereof |
| CN102716420A (en) * | 2012-06-19 | 2012-10-10 | 吴金虎 | Medicament for treating cyclomastopathy and hyperprolactinemia and preparation method of medicament |
| CN106075027A (en) * | 2016-07-19 | 2016-11-09 | 辽宁中医药大学 | A kind of Chinese medicine composition treating cyclomastopathy |
| CN106075027B (en) * | 2016-07-19 | 2019-10-11 | 辽宁中医药大学 | A kind of Chinese medicine composition for treating the proliferation of mammary gland |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101926872A (en) | Chinese medicinal detoxifying myo-regeneration paste for treating diabetic foot ulcer and preparation method thereof | |
| US11129863B2 (en) | Composition, preparation method thereof, and application thereof in the prevention and treatment of mammary gland disease | |
| CN102579560A (en) | Preparation method of Chinese angelica and astragalus mongholicus mixture aqueous extract, as well as application in intervening in pulmonary fibrosis | |
| CN1943708A (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN1302796C (en) | Traditional Chinese medicament for treating woman subhealthy faligue syndrome and its preparation method | |
| CN1718211A (en) | Traditional Chinese emdicine compounding prepns. for treating fracture | |
| CN114272295B (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN106138990B (en) | Rupikang solid dispersion preparation and preparation method thereof | |
| CN100471507C (en) | Traditional Chinese medicine prepn. for treating osteoporosis | |
| CN112386671B (en) | Traditional Chinese medicine composition for treating interstitial lung disease and application thereof | |
| CN115154528B (en) | A Chinese medicinal patch for external use for treating prostatitis and prostatic hyperplasia | |
| CN114848730B (en) | Preparation and application of compound traditional Chinese medicine composition for treating acute plasma cell mastitis | |
| CN102406790A (en) | Traditional Chinese medicine capsule for treating hyperplasia of mammary glands and preparation method thereof | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN112870250B (en) | Composition for preventing and treating organ fibrosis and application and preparation thereof | |
| CN114903939B (en) | New medical application of Jingfeng preparation | |
| CN1265309A (en) | Medicine for rheumatism and aploplexy and its preparation | |
| CN101822800B (en) | Medicine composite for treating breast disease and preparation method thereof | |
| CN109646539B (en) | Traditional Chinese medicine composition for improving local circulatory disturbance and preparation method and application thereof | |
| CN101099850A (en) | Medicine composition for treating chronic active hepatitis and early-stage hepatocirrhosis and preparation method thereof | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN101152246A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN1436565A (en) | Externally applied medicine for treating uterine erosion and its preparing method | |
| CN1248712C (en) | Medicine composition for curing splenomegaly | |
| CN112386672A (en) | Traditional Chinese medicine composition for treating interstitial lung disease and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |